Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation
Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiolo...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/15/4916 |
| _version_ | 1797586550698016768 |
|---|---|
| author | Farah Abuazzam Casey Dubrawka Tarek Abdulhadi Gwendolyn Amurao Louai Alrata Dema Yaseen Alsabbagh Omar Alomar Tarek Alhamad |
| author_facet | Farah Abuazzam Casey Dubrawka Tarek Abdulhadi Gwendolyn Amurao Louai Alrata Dema Yaseen Alsabbagh Omar Alomar Tarek Alhamad |
| author_sort | Farah Abuazzam |
| collection | DOAJ |
| description | Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials. |
| first_indexed | 2024-03-11T00:24:45Z |
| format | Article |
| id | doaj.art-c41f08217e4749e98be7f9698f39991c |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T00:24:45Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-c41f08217e4749e98be7f9698f39991c2023-11-18T23:06:56ZengMDPI AGJournal of Clinical Medicine2077-03832023-07-011215491610.3390/jcm12154916Emerging Therapies for Antibody-Mediated Rejection in Kidney TransplantationFarah Abuazzam0Casey Dubrawka1Tarek Abdulhadi2Gwendolyn Amurao3Louai Alrata4Dema Yaseen Alsabbagh5Omar Alomar6Tarek Alhamad7Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADepartment of Pharmacy, Barnes Jewish Hospital, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADivision of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USADespite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.https://www.mdpi.com/2077-0383/12/15/4916kidney transplantallograft rejectionT-cell mediated rejectionantibody-mediated rejectionmix rejectiontransplant immunology |
| spellingShingle | Farah Abuazzam Casey Dubrawka Tarek Abdulhadi Gwendolyn Amurao Louai Alrata Dema Yaseen Alsabbagh Omar Alomar Tarek Alhamad Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation Journal of Clinical Medicine kidney transplant allograft rejection T-cell mediated rejection antibody-mediated rejection mix rejection transplant immunology |
| title | Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation |
| title_full | Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation |
| title_fullStr | Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation |
| title_full_unstemmed | Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation |
| title_short | Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation |
| title_sort | emerging therapies for antibody mediated rejection in kidney transplantation |
| topic | kidney transplant allograft rejection T-cell mediated rejection antibody-mediated rejection mix rejection transplant immunology |
| url | https://www.mdpi.com/2077-0383/12/15/4916 |
| work_keys_str_mv | AT farahabuazzam emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT caseydubrawka emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT tarekabdulhadi emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT gwendolynamurao emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT louaialrata emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT demayaseenalsabbagh emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT omaralomar emergingtherapiesforantibodymediatedrejectioninkidneytransplantation AT tarekalhamad emergingtherapiesforantibodymediatedrejectioninkidneytransplantation |